Ljungman P, de la Camara R, Cordonnier C, Einsele H, Engelhard D, Reusser P, Styczynski J, Ward K
Department of Hematology, Karolinska University Hospital/Huddinge, Stockholm, Sweden.
Bone Marrow Transplant. 2008 Aug;42(4):227-40. doi: 10.1038/bmt.2008.162. Epub 2008 Jun 30.
These recommendations were prepared by the European Conference on Infections in Leukaemia following a predefined methodology. Literature searches were made to identify studies pertinent to management of CMV, HHV-6, -7 and -8 infections. For CMV, 76 studies were reviewed: 72 published and 4 presented as abstracts. Twenty-nine of these studies were prospective randomized trials. For the other herpesviruses, HHV-6, -7 and -8, no randomized controlled trial has been performed, although data from some studies with other primary endpoints have been used to assess the management of HHV-6 infection. Works presented only as abstracts were used to a very limited extent. The quality of evidence and level of recommendation were graded according to the Center for Disease Control (CDC) criteria.
这些建议由欧洲白血病感染会议按照预先确定的方法制定。进行了文献检索，以确定与巨细胞病毒（CMV）、人疱疹病毒6型（HHV-6）、7型（HHV-7）和8型（HHV-8）感染管理相关的研究。对于CMV，审查了76项研究：72项已发表，4项以摘要形式呈现。其中29项研究为前瞻性随机试验。对于其他疱疹病毒，HHV-6、HHV-7和HHV-8，尚未进行随机对照试验，尽管一些以其他主要终点为研究对象的研究数据已被用于评估HHV-6感染的管理。仅以摘要形式呈现的研究使用程度非常有限。证据质量和推荐等级根据疾病控制中心（CDC）标准进行分级。
